<DOC>
	<DOC>NCT00921414</DOC>
	<brief_summary>Randomized, open-label, phase III study to evaluate the efficacy of rituximab maintenance therapy in patients aged between 18 and 65 years inclusive undergoing first-line treatment for mantle cell lymphoma and exhibiting a response after autologous transplantation.</brief_summary>
	<brief_title>Mantel Cell Lymphoma Efficacy of Rituximab Maintenance</brief_title>
	<detailed_description>Demonstration of the superiority in terms of 4-year event-free survival (EFS) of Rituximab maintenance therapy compared to post-autograft surveillance in patients aged 18-65 years inclusive, treated with R-DHAP then autologous transplantation for MCL as first-line therapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>mantle cell lymphoma Initial immunophenotyping with CD20 and CD5. CD20+. t (11;14) by karyote, FISH, molecular biology or immunohistochemistry (Bcl1) Patient no previous treated. At least one tumor site accessible for assessment Aged &gt; 18 years &lt; 65 ECOG &lt; or = 2. No other neoplasms apart from resected basal cell carcinoma or in situ carcinoma. signed informed consent FEVG 50% other type of lymphoma ECOG &gt; or = 3 relapse serology VIH + Hepatite + diabetis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>R DHAP</keyword>
	<keyword>ASCT</keyword>
	<keyword>Rituximab Maintenance</keyword>
</DOC>